Caregen Q1 2026 Robust Performance, Pipeline Progress

Q1 2026 consolidated revenue KRW 22.7bn (+6.6% YoY), operating profit KRW 10.2bn (+85.8%), significant improvement
Net profit KRW 11.7bn, basic EPS KRW 239 (vs KRW 172 in Q1 2025)
Debt ratio at 14.41% (very low), zero borrowings, cash and equivalents KRW 13.1bn
Allowance for doubtful accounts maintained at KRW 12.58bn (26.6% of trade receivables); no further provisioning after large impairment in 2025
Recognized dividend payable of KRW 9.77bn for FY2025 (approx. KRW 200 per share), down from KRW 400 per share in FY2024
Treasury shares held: 4,844,216 shares (9.02%); no additional buyback or cancellation announced
Key pipeline: Korglutide (oral GLP-1) received FDA NDI registration in Jan 2026; wet AMD therapy preparing for Phase 2
USD strength benefits: 5% USD appreciation increases after-tax profit by KRW 1.94bn